<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toll-like receptors (TLRs) and signaling defects leading to primary immunodeficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toll-like receptors (TLRs) and signaling defects leading to primary immunodeficiency</h1>
<div class="graphic"><div class="figure"><div class="ttl">Toll-like receptors (TLRs) and signaling defects leading to primary immunodeficiency</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Infectious complications</td> <td class="subtitle1">Noninfectious clinical features</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Innate immunodeficiency</td> </tr> <tr> <td class="indent1">IRAK4 or MyD88</td> <td>AR</td> <td> <p>Recurrent severe infections (cellulitis, arthritis, meningitis, osteomyelitis, organ abscesses, and sepsis), mostly affecting upper respiratory tract and skin.</p> <p>Most common organisms: <em>Staphylococcus aureus</em>, <em>Streptococcus pneumoniae</em>, <em>Pseudomonas aeruginosa.</em></p> The lack of significant fever in the setting of a serious bacterial infection can be a clue.</td> <td>Presents in childhood; may improve with age if patient survives.</td> </tr> <tr> <td class="indent1">TLR3</td> <td>AR</td> <td>HSV encephalitis.</td> <td> </td> </tr> <tr> <td class="indent1">TRIF</td> <td>AD, AR</td> <td>HSV encephalitis.</td> <td> </td> </tr> <tr> <td class="indent1">TRAF3</td> <td>AD</td> <td>HSV encephalitis.</td> <td> </td> </tr> <tr> <td class="indent1">TBK1</td> <td>AD</td> <td>HSV encephalitis.</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">UNC93B1</td> <td>AR</td> <td>HSV encephalitis.</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Combined immunodeficiency</td> </tr> <tr> <td class="indent1">NEMO/IKK-gamma</td> <td>X-linked</td> <td> <p>Ba, MB, V, F, Op.</p> Severity and range of infectious complications is variable.</td> <td> <p>Incontinentia pigmenti in female infants.</p> Hypomorphic mutations in male infants often have (ED-ID).</td> </tr> <tr> <td class="indent1">I-kappa-B-alpha</td> <td>AD</td> <td>Ba, MB, V, F, Op.</td> <td>ED-ID.</td> </tr> <tr> <td class="indent1">NF-kappa-B1</td> <td>AD</td> <td>Recurrent Ba, V.</td> <td>Hypogammaglobulinemia.</td> </tr> <tr> <td class="indent1">NF-kappa-B2</td> <td>AD</td> <td>Ba, MB, V, F, Op.</td> <td> <p>Hypogammaglobulinemia.</p> <p>Autoimmunity.</p> Adrenal insufficiency.</td> </tr> <tr> <td class="indent1">HOIL-1<br/> <em>HOIP</em></td> <td>AR</td> <td>Pyogenic Ba (eg, <em>S. pneumoniae</em> or <em>Haemophilus influenzae</em>).</td> <td> <p>Autoinflammation (recurrent episodes of fever).</p> <p>Hepatosplenomegaly.</p> Muscular amylopectinosis.</td> </tr> <tr> <td class="indent1">DOCK8</td> <td>AR</td> <td>Pyogenic Ba, V, F.</td> <td> <p>Autosomal recessive hyperimmunoglobulin E.</p> Hypereosinophilia.</td> </tr> </tbody></table></div><div class="graphic_footnotes">IRAK4: interleukin-1 receptor-associated kinase 4; MyD88: myeloid differentiation primary response protein 88; AR: autosomal recessive; TLR3: toll-like receptor 3; HSV: herpes simplex virus; TRIF: toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter-inducing interferon-beta (IFN-beta); AD: autosomal dominant; TRAF3: tumor necrosis factor (TNF) receptor-associated factor 3; TBK1: tank-binding kinase 1; UNC93B1: UNC93 homolog B1; NEMO: nuclear factor (NF)-kappa-B essential modulator; IKK-gamma: inhibitor of NF-kappa-B kinase-gamma; Ba: bacteria; MB: mycobacteria; V: viral; F: fungal; Op: opportunistic infections; ED-ID: ectodermal dysplasia with immunodeficiency; NF: nuclear factor; HOIL-1: heme-oxidized iron-responsive element-binding protein 2 (IRP2) ubiquitin ligase 1, a component of the linear ubiquitination chain assembly complex (LUBAC); <em>HOIP</em>: the gene encoding the catalytic component of LUBAC; DOCK8: dedicator of cytokinesis 8.</div><div id="graphicVersion">Graphic 112782 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
